Clinical outcomes (n, %)
|
DM
|
No-DM
|
---|
G2‑DES
N = 1862
|
BP‑DES
N = 421
|
p
|
G2‑DES
N = 4232
|
BP‑DES
N = 1151
|
P
|
---|
MACE
|
219 (11.8)
|
60 (14.3)
|
0.159
|
403 (9.5)
|
129 (11.2)
|
0.089
|
All-cause death
|
27 (1.5)
|
6 (1.4)
|
0.969
|
40 (0.9)
|
16 (1.4)
|
0.187
|
Cardiac death
|
16 (0.9)
|
2 (0.5)
|
0.554
|
25 (0.6)
|
6 (0.5)
|
0.782
|
Non-fatal MI
|
37 (2.0)
|
15 (3.6)
|
0.050
|
75 (1.8)
|
17 (1.5)
|
0.493
|
ST
|
20 (1.1)
|
5 (1.2)
|
0.797
|
32 (0.8)
|
6 (0.5)
|
0.399
|
Revascularization
|
145 (7.8)
|
39 (9.3)
|
0.315
|
279 (6.6)
|
89 (7.7)
|
0.174
|
TVR
|
81 (4.4)
|
24 (5.7)
|
0.232
|
136 (3.2)
|
59 (5.1)
|
0.002
|
TLR
|
66 (3.5)
|
22 (5.2)
|
0.106
|
92 (2.2)
|
52 (4.5)
|
< 0.001
|
Stroke
|
26 (1.4)
|
4 (1.0)
|
0.468
|
51 (1.2)
|
15 (1.3)
|
0.789
|
Bleeding
|
124 (6.7)
|
21 (5.0)
|
0.204
|
310 (7.3)
|
79 (6.9)
|
0.592
|
BARC 2_5
|
50 (2.7)
|
8 (1.9)
|
0.355
|
123 (2.9)
|
31 (2.7)
|
0.701
|
BARC 3_5
|
8 (0.4)
|
1 (0.2)
|
> 0.999
|
24 (0.6)
|
4 (0.3)
|
0.358
|
- DM diabetes mellitus, G2-DES second generation drug-eluting stent, BP-DES biodegradable polymer drug-eluting stent, MACE major adverse cardiac events, MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, TLR target lesion revascularization, BARC Bleeding Academic Research Consortium definition